CORT Quote, Financials, Valuation and Earnings

Integer Holdings Corp. has a net margin of 11.83% compared to Corcept Therapeutics, Inc.'s net margin of 10.32%. Corcept Therapeutics, Inc.'s return on equity of 14.97% beat Integer Holdings Corp.'s return on equity of 6.11%.

Corcept Therapeutics, Inc. has a consensus price target of $67.40, signalling upside risk potential of 58.63%. On the other hand Integer Holdings Corp. has an analysts' consensus of $93.25 which suggests that it could grow by 7.37%. Given that Corcept Therapeutics, Inc. has higher upside potential than Integer Holdings Corp., analysts believe Corcept Therapeutics, Inc. is more attractive than Integer Holdings Corp..

Corcept Therapeutics, Inc. has a beta of 0.249, which suggesting that the stock is 75.089% less volatile than S&P 500. In comparison Integer Holdings Corp. has a beta of 0.710, suggesting its less volatile than the S&P 500 by 28.956%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Integer Holdings Corp. pays out -- of its earnings as a dividend.

Corcept Therapeutics, Inc. quarterly revenues are $202.1M, which are smaller than Integer Holdings Corp. quarterly revenues of $470.9M. Corcept Therapeutics, Inc.'s net income of $23.9M is lower than Integer Holdings Corp.'s net income of $48.6M. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 52.54x while Integer Holdings Corp.'s PE ratio is 30.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 6.77x versus 1.66x for Integer Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 11.83% compared to Corcept Therapeutics, Inc.'s net margin of 18.15%. Corcept Therapeutics, Inc.'s return on equity of 14.97% beat Merck & Co., Inc.'s return on equity of 36.76%.

Corcept Therapeutics, Inc. has a consensus price target of $67.40, signalling upside risk potential of 58.63%. On the other hand Merck & Co., Inc. has an analysts' consensus of $128.59 which suggests that it could grow by 6.11%. Given that Corcept Therapeutics, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Merck & Co., Inc..

Corcept Therapeutics, Inc. has a beta of 0.249, which suggesting that the stock is 75.089% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.446%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.74% to investors and pays a quarterly dividend of $0.85 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Corcept Therapeutics, Inc. quarterly revenues are $202.1M, which are smaller than Merck & Co., Inc. quarterly revenues of $16.3B. Corcept Therapeutics, Inc.'s net income of $23.9M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 52.54x while Merck & Co., Inc.'s PE ratio is 16.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 6.77x versus 4.67x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical, Inc. has a net margin of 11.83% compared to Corcept Therapeutics, Inc.'s net margin of -62.32%. Corcept Therapeutics, Inc.'s return on equity of 14.97% beat Ultragenyx Pharmaceutical, Inc.'s return on equity of -558.7%.

Corcept Therapeutics, Inc. has a consensus price target of $67.40, signalling upside risk potential of 58.63%. On the other hand Ultragenyx Pharmaceutical, Inc. has an analysts' consensus of $52.45 which suggests that it could grow by 133.63%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Corcept Therapeutics, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Corcept Therapeutics, Inc..

Corcept Therapeutics, Inc. has a beta of 0.249, which suggesting that the stock is 75.089% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical, Inc. has a beta of 0.248, suggesting its less volatile than the S&P 500 by 75.224%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

Corcept Therapeutics, Inc. quarterly revenues are $202.1M, which are smaller than Ultragenyx Pharmaceutical, Inc. quarterly revenues of $207M. Corcept Therapeutics, Inc.'s net income of $23.9M is higher than Ultragenyx Pharmaceutical, Inc.'s net income of -$129M. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 52.54x while Ultragenyx Pharmaceutical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 6.77x versus 3.45x for Ultragenyx Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Terns Pharmaceuticals, Inc. has a net margin of 11.83% compared to Corcept Therapeutics, Inc.'s net margin of --. Corcept Therapeutics, Inc.'s return on equity of 14.97% beat Terns Pharmaceuticals, Inc.'s return on equity of -29.05%.

Corcept Therapeutics, Inc. has a consensus price target of $67.40, signalling upside risk potential of 58.63%. On the other hand Terns Pharmaceuticals, Inc. has an analysts' consensus of $54.25 which suggests that it could grow by 2.9%. Given that Corcept Therapeutics, Inc. has higher upside potential than Terns Pharmaceuticals, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Terns Pharmaceuticals, Inc..

Corcept Therapeutics, Inc. has a beta of 0.249, which suggesting that the stock is 75.089% less volatile than S&P 500. In comparison Terns Pharmaceuticals, Inc. has a beta of -0.370, suggesting its less volatile than the S&P 500 by 136.957%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Terns Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Corcept Therapeutics, Inc. quarterly revenues are $202.1M, which are larger than Terns Pharmaceuticals, Inc. quarterly revenues of --. Corcept Therapeutics, Inc.'s net income of $23.9M is higher than Terns Pharmaceuticals, Inc.'s net income of -$24.6M. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 52.54x while Terns Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 6.77x versus -- for Terns Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.